Twelve patients with various types of lymphoma were treated with etretinate. The diagnosis included parapsoriasis en plaque, epidermotropic lymphoma (diffuse chronic erythroderma with atypical mononuclear cells, Sézary syndrome or MF tumours) and non-epidermotropic lymphoma. The patients received etretinate in a dose of 0.8 to 1.0 mg/kg/day for 2 to 14 months. No additional therapy was given. Patients with epidermotropic lymphomas stage I and II had a favourable clinical and histological response whereas those with deeply infiltrating tumours remained unresponsive. Patients with parapsoriasis en plaque and poikiloderma showed little response. Of the four patients who discontinued the treatment, three had recurrences after 3 to 4 months but one remained clear. The results obtained with etretinate may equal those obtained with more aggressive treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2133.1983.tb03991.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parapsoriasis en plaque, deciphered at single-cell resolution.
J Allergy Clin Immunol
December 2024
Department of Dermatology, University of California, San Francisco, Calif. Electronic address:
A clinical case of pityriasis lichenoides chronica presenting with palpable purpura after streptococcal infection.
Folia Med (Plovdiv)
June 2024
Sofiamed University Hospital, St Kliment Ohridski University, Sofia, Bulgaria.
Article Synopsis
- Pityriasis lichenoides is a rare inflammatory skin condition characterized by red-brown papules and crusty lesions as they evolve over time.
- A 60-year-old woman developed the chronic form of this condition ten days after suffering from streptococcal pharyngitis, starting with purple spots on her legs and later developing red, scaly patches on other parts of her body.
- After treatment with methylprednisolone and hydroxychloroquine, her skin lesions improved significantly and did not return.
Single-cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis disease group.
J Allergy Clin Immunol
September 2024
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:
Article Synopsis
- Mycosis fungoides (MF), a type of skin cancer, is often misdiagnosed early on because it resembles conditions like atopic dermatitis (AD), complicating the distinction from parapsoriasis, which can appear in small or large plaques.
- The study used single-cell RNA sequencing to analyze skin samples from patients showing both parapsoriasis and early-stage MF to better understand these diseases.
- Results showed that large-plaque lesions tended to have signs of early-stage MF while small-plaque lesions were more diverse and lacked cancerous characteristics, leading researchers to propose the term "polyclonal parapsoriasis en plaque" for these unique lesions.
Time-dependent change of T cell receptor clonality: From large plaque parapsoriasis to early mycosis fungoides.
Skin Res Technol
August 2024
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.
Clin Exp Med
July 2024
Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Patients with primary cutaneous T-cell lymphoma (CTCL) often experience severe and difficult-to-treat pruritus that negatively affects their quality of life (QoL). However, the mechanisms of pruritus in CTCL, including mycosis fungoides (MF), remain largely unknown, and detailed characteristics of CTCL-associated pruritus is not fully elucidated. To characterize pruritus in CTCL, cutaneous B-cell lymphoma (CBCL), and large plaque parapsoriasis (LPP), and to identify potential itch mediators involved in the pathogenesis of pruritus in CTCL patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!